Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Podcast TCTMD Talking Points

The COBRA-REDUCE Trial

December 01, 2021

News Industry News

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

May 13, 2021

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Presenter: Robert Byrne

October 17, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

News Industry News

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

May 24, 2018

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

Presentation

9-Month Clinical and Angiographic Outcomes With Cobra Polyzene-F Stent

Presenter: Donald Cutlip

February 03, 2017

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

News Industry News

CeloNova’s Coronary Stent System Could Mean Faster Healing of Arteries and Greatly Reduced Use of Blood-thinning Medication

March 18, 2014

Video

» Interview

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

October 17, 2020

Advertisement

The COBRA-REDUCE Trial

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

9-Month Clinical and Angiographic Outcomes With Cobra Polyzene-F Stent

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

CeloNova’s Coronary Stent System Could Mean Faster Healing of Arteries and Greatly Reduced Use of Blood-thinning Medication

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content